期刊文献+

聚乙二醇干扰素治疗慢性丙型肝炎临床疗效、影响因素及安全性分析(附89例临床分析) 被引量:28

Efficacy, influencing factors and safety of PEG-INF alpha-2a (PEG-INF-2a) in the treatment of chronic hepatitis C:analysis of 89 patients
收藏 分享 导出
摘要 目的 观察聚乙二醇干扰素(PEG IFN)α-2a治疗慢性丙型肝炎的效果、疗效影响因素及安全性.方法 观察了89例慢性丙肝患者,对46例慢性丙肝患者予PEG IFNα-2a(180μg或135μg/周)联合利巴韦林(RBV)900mg/d抗病毒治疗,对照组为43例慢性丙肝患者予IFNα-2a(5 MIU/隔天)联合RBV 900mg/d抗病毒治疗.疗程48周,随访24周.两组治疗前HCV-RNA、基因型等临床资料具有可比性,以病毒学应答和生化学应答作为疗效的主要评价指标.同时观察药物不良反应.结果 PEG IFNα-2a组持续应答率(SVR)显著高于IFNα-2a组(分别是56.5%和19.5%,P<0.0001).PEGIFNα-2a组治疗基因1型、高病毒载量慢性丙型肝炎的SVR明显高于IFNd-2a组(P<0.001),但非基因1型、低病毒载量的SVR两组之间差异无统计学意义(P值分别为0.664、0.116).PEG IFNα-2a与IFNα-2a有相似的不良反应,但除白细胞减少的程度及体重减轻发生率PEG IFNα-2a组高于IFNα-2a组外(P值为0.001),余不良反应间差异无统计学意义.结论 PEG IFNα-2a对慢性丙型肝炎患者的疗效优于干扰素IFNα-2a,尤其对基因1型、高病毒载量的患者更应选择PEG IFNα-2a,且具有较好的安全性和耐受性. Objective To investigate the efficacy, influencing factors and safety of PEG-INF alpha-2a (PEG-INF-2a) in the treatment of hepatitis C. Methods Totally 89 patients with hepatitis C were included in this study and 46 patients were treated with PEG-INF-2a ( 180 μg or 135 μg/week) and RBV 900 mg/d, 43 patients were treated with IFNα-2a (5 MIU/qod)and RBV 900 mg/d. The time of treatment was 48 weeks, and all the patients were visited 24 weeks after treatment. There were no significant difference between the two groups in pretreatment HCV-RNA, HCV genotype and other clinical data. The main parameters to evaluate the efficacy were virological and biochemical responses. The side effects were intensively observed. Results Sustained virological response (SVR) rate in PEG-IFNα-2a group was significantly higher than that in IFNα-2a group (56.5% and 19.5% respectively, P 〈 0.001). As the patients were divided according to HCV genotype 1 and high virus load, the SVR rate of PEG-IFNα-2a group was higher than IFNα-2a group ( P 〈 0.001 ). However, there was no significant difference between two groups in the patients with non-genotype 1 and low viral load ( P = 0.664, 0.116). Similar side-effects were observed in PEG IFNα-2a group and IFNα-2a group, but the rate of weight decline and the degree of leukocyte decrease were more significant in PEG IFNα-2a group than in IFNα-2a group ( P = 0.001 ). Conclusion The efficacy of PEG IFNα-2a in the treatment of chronic hepatitis C is superior to that of conventional IFNα-2a, PEG-IFNα-2a had good tolerance and safety profiles.
作者 马丽娜 陈新月 陈杰 沈成利 汪俊韬 MA Li-na , CHEN Xin-yue , CHEN Jie,  SHEN Cheng-li , WANG Jun-tao (Beijing Youan Hospial, Capialtal University of Medical Sciences, Beijing 100054, China)
出处 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2006年第2期 42-45,共4页 Chinese Journal of Experimental and Clinical Virology
关键词 肝炎 丙型 干扰素Α-2A 临床试验 Hepatitis C Interferom Alfa-2a Clinical trials
作者简介 通讯作者:陈新月,E-mail:chenxy63050639@yahoo.com.cn。
  • 相关文献

参考文献5

二级参考文献63

  • 1成军,斯崇文.抗病毒基因治疗研究进展[J].中华实验和临床病毒学杂志,1993,7(4):436-439. 被引量:7
  • 2成军.HCV RNA定量PCR检测研究进展[J].国外医学:流行病学.传染病学分册,1994,21(1):20-23. 被引量:8
  • 3成军,.丙型肝炎病毒基因组的翻译及其产物的加工[J].国外医学:微生物学分册,1995,18(4):14-16. 被引量:20
  • 4钟彦伟 成军 等.HCV非结构蛋白NS3人源单链抗体的筛选与鉴定[J].中华传染病杂志,2000,18:12-15. 被引量:23
  • 5钟彦伟 王松山 等.抗丙肝病毒非结构蛋白NS3单链抗体的制备及免疫组织化学研究[J].中华实验与临床病毒学杂志,2001,15(2):97-99. 被引量:11
  • 6成军.丙型肝炎病毒干扰素敏感决定区的研究进展[J].国外医学:流行病学.传染病学分册,2000,27:55-58. 被引量:13
  • 7成军 张玲霞.HCV的基因治疗方案-从HCV-肝细胞相互作用的分子生物学机制设计[J].国外医学:流行病学.传染病学分册,1999,26:59-61. 被引量:1
  • 8钟彦伟 成军 等.应用噬菌体表面展示技术筛选丙型肝炎病毒NS5A抗原模拟表达[J].世界华人消化杂志,2002,10:133-136. 被引量:1
  • 9李克 张玲霞 等.丙型肝炎病毒与脂质系统代谢关系的研究[J].国外医学:病毒学分册,2002,9:1-3. 被引量:1
  • 10Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869. 被引量:1

共引文献778

同被引文献316

引证文献28

二级引证文献74

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈